Freenome

Freenome (Nasdaq: FRNM) is a publicly traded company developing blood-based tests for early cancer detection. It combines biology, artificial intelligence, and machine learning to develop screening tests tailored to individual cancers.

Its SimpleScreen CRC blood test is FDA-approved for colorectal cancer screening in adults aged 45 and older who are at average risk. A positive result should be followed by colonoscopy; the test does not replace diagnostic colonoscopy or surveillance colonoscopy for high-risk individuals.

Freenome is also developing tests for lung cancer and other indications. These investigational programs are distinct from its approved colorectal cancer screening test.